Latest News for PHYOF
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a neuroscience imaging and biomarker analytics company, has confirmed its revenue guidance remains unchanged after...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a neuroscience imaging and biomarker analytics company, has confirmed its revenue guidance remains unchanged after two clients discontinued Huntington's disease programmes it was supporting. The AIM-listed company said the cancellations would reduce its contracted order book by around £1.5 million over the next two financial years.
South32 Ltd (LSE:S32, ASX:S32, FRA:32Z, OTC:SHTLF, JSE:S32) has secured a major US federal approval for its US$4.7 billion Hermosa critical minerals project...
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging company, rose 11% to 9p after it has raised its revenue forecast for the...
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging company, has raised its revenue forecast for the current financial year after stronger-than-expected trading. The company now expects revenues of at least £8 million for the year ending 30 September 2026.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PHYOF.
Senate Trading
No Senate trades found for PHYOF.
U.S. House Trading
No House trades found for PHYOF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.